ADVA
15.12.2020 09:02:11 CET | Business Wire | Press release
ADVA (FSE: ADV) today launched a unique set of edge and access network synchronization devices with enhanced capabilities for next-generation applications such as 5G. The latest Oscilloquartz solutions address key challenges for a wide range of industries by bringing new levels of timing accuracy and resilience to edge networks. The OSA 5412 and 5422 offer precise phase, frequency and time-of-day synchronization and can be used for time-as-a-service applications. For the first time, communication service providers, enterprises, broadcast networks and power utilities can deploy synchronization technology at the edge that features multi-band GNSS receivers for nanosecond accuracy. The OSA 5412 and 5422 utilize in-service sync probing and assurance as well as innovative GNSS assurance capabilities. The products also provide support for eight field-upgradeable 10Gbit/s ports, ensuring the scale and efficiency needed for next-generation smart grids, industrial IoT applications and 5G connectivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215005081/en/
“Our latest solutions build on the great success we’ve had with our access synchronization product line. Now operators can harness the power of multi-band GNSS receivers to deliver highly accurate, UTC-traceable timing at the network edge. That enables the availability and precision that will be essential for tomorrow’s services,” said Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. “By extending the feature set of our edge technology, we’re empowering CSPs to smoothly transition to the reliability and accuracy required for 5G and, at the same time, enabling our unique innovation to be used across a wide range of verticals. With support for 10Gbit/s and 1Gbit/s interfaces as well as hardware timestamping, our access timing products are the ultimate in future-proof, space-efficient synchronization.”
The OSA 5412 is a highly flexible access network synchronization solution that offers compact and cost-effective timing distribution and assurance. The OSA 5422 is engineered for the most extreme conditions. It meets stringent frequency and phase synchronization requirements, delivers the best holdover performance of any edge device on the market, and supports multiple legacy interfaces such BITS and IRIG. Both solutions address new ITU-T specifications, including for class A and B PRTCs, ePRTCs with strict holdover requirements, and the newly improved class C and D boundary clocks. They also feature onboard multi-band, multi-constellation GNSS receivers that overcome ionospheric delay variation far more cost-efficiently than rival solutions using high-end rubidium oscillators. The OSA 5412 and 5422 support multiple PTP profiles, NTP and SyncE with the highest number of 1/10GbE ports on the market. What’s more, both devices are engineered with optional OLED display and with hot-swappable modules and power supplies to be easily upgraded in the field.
“Access grandmaster clocks need to meet stricter demands for accuracy and reliability than ever before, and many industries have their own specific set of stringent timing requirements. That’s why we’ve evolved our portfolio of edge and access network synchronization solutions for the specific challenges of the 5G era,” commented Gil Biran, general manager, Oscilloquartz, ADVA. “Our OSA 5412 and 5422 answer the most urgent timing needs of mission-critical infrastructure in multiple verticals. They provide nanosecond precision, an abundance of fan-out interface options and operational simplicity thanks to the management and monitoring capabilities of our Ensemble Controller with Sync Director. Operators of broadcast, healthcare, financial networks and more now have a straightforward and affordable path from legacy to next-generation timing.”
Further information on the OSA 5412 and 5422 is available in these slides: https://adva.li/osa-5412-5422-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005081/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom